- Current report filing (8-K)
December 06 2010 - 6:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 6, 2010 (December 1,
2010)
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-51312
|
|
54-2155579
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
262400
The
People’s Republic of China
(Address
of principal executive offices, including zip code)
(86)
536-6295802
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On
December 1, 2010, YE Hu offered his resignation as Chief Financial Officer
of Shengtai Pharmaceutical, Inc. (the “
Company
”), with an effective
date of December 31, 2010. The Board of Directors of the Company has
accepted his resignation and is actively searching for a new Chief Financial
Officer. Yongqiang Wang, the Financial Controller of the Company,
will act as principal financial officer until such time as the Board has
appointed a new Chief Financial Officer.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
|
|
Dated:
December 6, 2010
|
|
|
|
|
By:
|
/s/
Qingtai
Liu
|
|
|
Name:
Qingtai Liu
|
|
Title:
Chief Executive
Officer
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Sep 2023 to Sep 2024